PIONEERING INNOVATION IN CARDIOMETABOLIC DRUG RESEARCH & DEVELOPMENT

Based in Lille (France) and Cambridge (MA, USA), Genfit was co-founded in 1999 by Professor. Jean-Charles Fruchart, Mr. Jean-François Mouney, Professor Bart Staels and Mrs. Florence Séjourné, who have many years combined experience in both business and science. Genfit is today a renowned European biotech leader, focused on finding novel treatments for major cardiovascular, metabolic and inflammatory diseases, as well as age-linked neurodegenerative disorders.

The value of the company's drug discovery engine has been validated by pharmaceutical leaders who have entrusted us with a number of innovative research and drug development alliance programmes, producing a strong project portfolio of first-in-class drug candidates. Pharmaceutical companies who have become long-term strategic partners include: Sanofi-Aventis, Fournier Laboratories, Merck KGaA, Pierre-Fabre and Servier Laboratories.

The most advanced proprietary programmes at Genfit are focused on addressing unmet medical needs in cardiometabolic disease and related disorders: Type II diabetes, hypertension, atherosclerosis, dyslipidemia and obesity. The company has adopted an innovative multimodal drug discovery approach that targets several of these indications simultaneously.

Genfit's continuous track record of building incremental value through multiple routes is further strengthened by a broad intellectual property framework, a diverse and rich proprietary pipeline and strong financial performance and resources. 

KEY FACTS

• Creation: 1999
• Employees: 140 (including 111 scientists)
• Location:
  • Headquartered in Lille (France)
  • Subsidiary in Cambridge (USA)
  • 7000m² state-of-the-art laboratories
• 2006 Financials
• Total revenues:    € 11.422 K
• Net Profit:                    € 335 K

GENFIT CORP: AN INTERNATIONAL PRESENCE

Genfit is committed to partnering with academia, biotechnology and pharmaceutical companies worldwide. Genfit Corp., based in Cambridge (MA), is our local interface with leading institutes and companies in the North American marketplace. Our proximity to this world-renowned hub between the academic research community, leading hospitals and local biopharma firms offers many competitive advantages. The combination of technology and medicine makes this the perfect environment for therapeutic biotechnological innovation. Genfit Corp. participates in leading national pharma events, leveraging its strategic location and our scientific expertise to develop and expand academic and industry collaborative opportunities in the USA.